Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

574
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
574
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

542
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
542
Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

1.3K
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
1.3K
Classification of Illness01:17

Classification of Illness

8.9K
The meaning of illness is individualized to each person who experiences an alteration in health. In contrast, disease is a medical term indicating a pathological change in the structure and function of the body or mind. It is a condition that has specific symptoms and boundaries.
An illness is a response to a disease in which the person's level of functioning is changed compared with a previous level. The general classification of illness includes acute and chronic.
Acute illness is severe...
8.9K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

607
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
607
Autoimmune Disorders01:29

Autoimmune Disorders

1.9K
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
1.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

What is the best way to plan a 12-month clinical drug trial in JIA associated uveitis?

Expert review of clinical immunology·2026
Same author

Improving early detection of temporomandibular joint involvement in juvenile idiopathic arthritis with a clinically interpretable machine learning model.

Scientific reports·2025
Same author

Childhood-onset Takayasu arteritis: clinical presentation, challenges and disease course.

Pediatric rheumatology online journal·2025
Same author

[The role of Janus kinase inhibitors in the treatment of juvenile idiopathic arthritis].

Ugeskrift for laeger·2025
Same author

Age at diagnosis as a prognostic factor in selected categories of juvenile idiopathic arthritis.

RMD open·2025
Same author

Long-term efficacy and safety of colchicine and anti-IL-1 blockers in FMF: results from the Eurofever multicenter observational study.

Journal of autoimmunity·2025

Related Experiment Video

Updated: Feb 19, 2026

Induction and Clinical Scoring of Chronic-Relapsing Experimental Autoimmune Encephalomyelitis
26:48

Induction and Clinical Scoring of Chronic-Relapsing Experimental Autoimmune Encephalomyelitis

Published on: July 4, 2007

18.8K

Clinical Outcome and Long-term Remission in JIA.

Mia Glerup1, T Herlin2, M Twilt2,3

  • 1Department of Pediatrics, Aarhus University Hospital, Palle Juul-Jensens Blvd 99, 8200, Aarhus, Denmark. miagleru@rm.dk.

Current Rheumatology Reports
|November 5, 2017
PubMed
Summary

Achieving inactive disease in juvenile idiopathic arthritis (JIA) remains challenging, with many patients showing active disease even after long-term follow-up. Enhancing early treatment strategies is crucial for improving long-term outcomes in JIA patients.

Keywords:
ArthritisChildhoodJuvenile idiopathic arthritisOutcomeRemission

More Related Videos

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
04:50

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

1.2K
Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice
08:43

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice

Published on: January 31, 2020

7.4K

Related Experiment Videos

Last Updated: Feb 19, 2026

Induction and Clinical Scoring of Chronic-Relapsing Experimental Autoimmune Encephalomyelitis
26:48

Induction and Clinical Scoring of Chronic-Relapsing Experimental Autoimmune Encephalomyelitis

Published on: July 4, 2007

18.8K
Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
04:50

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

1.2K
Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice
08:43

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice

Published on: January 31, 2020

7.4K

Area of Science:

  • Pediatric Rheumatology
  • Clinical Immunology
  • Longitudinal Study Design

Background:

  • Juvenile idiopathic arthritis (JIA) is a heterogeneous autoimmune disease affecting children.
  • Long-term remission and predictors of clinical outcome in JIA are critical for effective management.
  • Treatment protocols have evolved, particularly with the advent of biologic therapies.

Purpose of the Study:

  • To review and assess long-term remission rates in patients with juvenile idiopathic arthritis (JIA).
  • To identify predictors of clinical outcome and inactive disease in JIA.
  • To evaluate the effectiveness of current treatment strategies in achieving sustained remission.

Main Methods:

  • Comprehensive literature search of studies published between January 1, 2004, and February 28, 2017.
  • Inclusion of studies with a minimum follow-up period of 24 months.
  • Independent selection of studies by two reviewers based on predefined inclusion and exclusion criteria.

Main Results:

  • Achieving inactive disease or clinical remission is dependent on JIA subtype.
  • A significant proportion of JIA patients exhibit active disease at long-term follow-up.
  • Despite treatment advancements, many JIA patients do not achieve inactive disease within two years of diagnosis.

Conclusions:

  • Long-term outcomes in JIA remain challenging due to study heterogeneity.
  • While improvements are noted in the biologic era, enhancing early remission rates is essential.
  • Further research is needed to optimize treatment strategies for achieving sustained inactive disease in JIA.